Alterity Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K covers the month of September 2026 for Alterity Therapeutics Limited, a development stage enterprise headquartered in Melbourne, Australia. The filing is incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate actions rather than financial performance data.
Material Changes
The primary material event disclosed is the submission of an application for the quotation of securities (ATH) on the Australian Securities Exchange, included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves primarily as a notification of the securities quotation application.
Key Investor Verification Points
- Confirm the status and approval of the application for quotation of securities (ATH) referenced in Exhibit 99.1.
- Verify the company's current cash position and runway, as no financial metrics are included in this specific filing.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for details on outstanding equity and potential dilution.